Analysts See $-0.01 EPS for ProMIS Neurosciences, Inc. (PMN); Ipass (IPAS) Sentiment Is 0.76

April 17, 2018 - By Richard Conner

ProMIS Neurosciences, Inc. (TSE:PMN) Logo

Analysts expect ProMIS Neurosciences, Inc. (TSE:PMN) to report $-0.01 EPS on May, 8.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.01 EPS. After having $-0.01 EPS previously, ProMIS Neurosciences, Inc.’s analysts see 0.00% EPS growth. The stock increased 2.53% or $0.01 during the last trading session, reaching $0.405. About 124,850 shares traded. ProMIS Neurosciences, Inc. (TSE:PMN) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Ipass Inc (IPAS) investors sentiment increased to 0.76 in Q4 2017. It’s up 0.11, from 0.65 in 2017Q3. The ratio improved, as 13 funds increased or started new positions, while 17 sold and trimmed equity positions in Ipass Inc. The funds in our database now have: 10.44 million shares, down from 17.21 million shares in 2017Q3. Also, the number of funds holding Ipass Inc in top ten positions decreased from 1 to 0 for a decrease of 1. Sold All: 11 Reduced: 6 Increased: 5 New Position: 8.

iPass Inc. provides mobile connectivity that enables Wi-Fi access on various mobile devices in the United States and internationally. The company has market cap of $26.24 million. The firm offers mobile connectivity services that provide cloud solution allowing clients and their users access to its Wi-Fi network to stay connected to the people and information. It currently has negative earnings. It offers business to business mobile connectivity solutions to large and small enterprises, as well as to strategic partnerships comprising original equipment manufacturers, loyalty programs, software product and service providers, and communication companies; and iPass SmartConnect that takes the guesswork out of Wi-Fi automatically connecting clients to the hotspot for their needs.

Analysts await iPass Inc. (NASDAQ:IPAS) to report earnings on May, 2. They expect $-0.04 EPS, up 42.86% or $0.03 from last year’s $-0.07 per share. After $-0.06 actual EPS reported by iPass Inc. for the previous quarter, Wall Street now forecasts -33.33% EPS growth.

Goldman Capital Management Inc holds 0.4% of its portfolio in iPass Inc. for 801,000 shares. Adirondack Research & Management Inc. owns 1.13 million shares or 0.23% of their US portfolio. Moreover, White Pine Capital Llc has 0.01% invested in the company for 35,000 shares. The Colorado-based Amg National Trust Bank has invested 0% in the stock. Bank Of New York Mellon Corp, a New York-based fund reported 53,977 shares.

The stock increased 3.87% or $0.0139 during the last trading session, reaching $0.373. About 323,590 shares traded. iPass Inc. (IPAS) has declined 67.50% since April 17, 2017 and is downtrending. It has underperformed by 79.05% the S&P500.

Ratings analysis reveals 50% of iPass’s analysts are positive. Out of 2 Wall Street analysts rating iPass, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. IPAS was included in 2 notes of analysts from October 19, 2016. The company was initiated on Wednesday, October 19 by Maxim Group. The company was downgraded on Friday, December 16 by Chardan Capital Markets.

ProMIS Neurosciences Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for treatment of neurodegenerative diseases, primarily Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company has market cap of $91.55 million. The Company’s proprietary target discovery engine is based on the use of two complementary techniques. It currently has negative earnings. The firm applies its thermodynamic, computational discovery platform?ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins.

iPass Inc. (NASDAQ:IPAS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: